The need for rigorous and accurate characterization of STK11 functional status is now urgent as clinical decisions governing the use of anti-PD-1 monoclonal antibody therapy for patients with KRAS-driven lung adenocarcinoma have come to depend upon accurate STK11 functional evaluation. Here, KRAS is linked to lung adenocarcinoma.